Adocia | Balance Sheet

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
19,415.00
49,800.00
72,062.00
58,037.00
34,778.00
39,841
Total Accounts Receivable
3,477.00
514.00
12,887.00
11,378.00
8,868.00
19,287
Inventories
393.00
144.00
353.00
404.00
397.00
378
Other Current Assets
250.00
300.00
681.00
189.00
649.00
1,478
Total Current Assets
23,535.00
50,758.00
85,983.00
70,008.00
44,692.00
60,984
Net Property, Plant & Equipment
946.00
975.00
1,930.00
8,790.00
8,975.00
8,726
Total Investments and Advances
-
809.00
182.00
-
29.00
218
Intangible Assets
3.00
2.00
-
-
65.00
115
Other Assets
245.00
-
-
-
-
-
Total Assets
24,729.00
52,544.00
88,095.00
78,798.00
53,761.00
70,043
ST Debt & Current Portion LT Debt
503.00
1,684.00
135.00
791.00
1,791.00
Accounts Payable
1,784.00
2,649.00
5,461.00
4,572.00
4,931.00
Other Current Liabilities
1,245.00
15,014.00
14,811.00
22,654.00
2,160.00
Total Current Liabilities
3,532.00
19,347.00
20,407.00
28,017.00
8,882.00
Long-Term Debt
1,814.00
728.00
702.00
6,281.00
5,781.00
Provision for Risks & Charges
253.00
396.00
1,095.00
1,738.00
2,241.00
Other Liabilities
-
29,568.00
18,839.00
-
-
Total Liabilities
5,599.00
50,039.00
41,043.00
36,036.00
16,904.00
Common Equity (Total)
19,130.00
2,505.00
47,052.00
42,762.00
36,857.00
Total Shareholders' Equity
19,130.00
2,505.00
47,052.00
42,762.00
36,857.00
Total Equity
19,130.00
2,505.00
47,052.00
42,762.00
36,857.00
Liabilities & Shareholders' Equity
24,729.00
52,544.00
88,095.00
78,798.00
53,761.00

About Adocia

View Profile
Address
115 avenue Lacassagne
Lyon Rhone-Alpes 69003
France
Employees -
Website http://www.adocia.com
Updated 07/08/2019
Adocia SA is a clinical-stage biotechnology company, which engages in the development of medicines from already-approved therapeutic proteins and peptides. Its product pipelines include: BioChaperone Lispro; BioChaperone Combo; HinsBet; BioChaperone Human Glucagon; BioChaperone Glargine GLP-1; and BioChaperone Prandaial Combinations for T1D. The company was founded by Gérard, Olivier, and Rémi Soula on December 16, 2005 and is headquartered in Lyon, France.